Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2023 03:04 ET | Source: Sosei Group Corporation

Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023

Tokyo, Japan, and Cambridge, UK, 18 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused...
October 10, 2023 02:30 ET | Source: Sosei Group Corporation

Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration

The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality novel chemistry...
September 20, 2023 02:30 ET | Source: Sosei Group Corporation

Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board

Tokyo, Japan and Cambridge, UK, 20 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on...
September 11, 2023 19:01 ET | Source: Sosei Group Corporation

Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric...
August 10, 2023 02:52 ET | Source: Sosei Group Corporation

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10...
August 04, 2023 02:37 ET | Source: Sosei Group Corporation

Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023

Tokyo, Japan and Cambridge, UK, 4 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
July 20, 2023 02:31 ET | Source: Sosei Group Corporation

Sosei Heptares - Investor and Press Conference on Today’s Announcement Regarding the Acquisition and License Transaction with Idorsia

Tokyo, Japan and Cambridge, UK, 20 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today’s announcement; “Sosei Heptares Acquires...
July 20, 2023 02:30 ET | Source: Sosei Group Corporation

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company

Transaction adds complementary late-stage clinical development capability with profitable and fast-growing commercial operations in JapanLean, go-to-market commercial model, well positioned to scale...
July 11, 2023 03:00 ET | Source: Sosei Group Corporation

Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results

Tokyo, Japan and Cambridge, UK, 11 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June...
July 02, 2023 20:23 ET | Source: Sosei Group Corporation

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated...